id: NEW:oral_nicotine_pouch_access_to_NEW:population_smoking_prevalence
name: Oral Nicotine Pouch Market Access â†’ Population Smoking Prevalence
from_node:
  node_id: NEW:oral_nicotine_pouch_access
  node_name: Oral Nicotine Pouch Market Access
to_node:
  node_id: NEW:population_smoking_prevalence
  node_name: Population Smoking Prevalence
direction: positive
category: political
mechanism_pathway:
- 'Step 1: ONP products enter market and become commercially available (since 2016 globally)'
- 'Step 2: Population-level exposure to alternative nicotine products increases'
- 'Step 3: Potential substitution effects at population level'
- 'Step 4: Theoretical impact on combustible tobacco prevalence (direction uncertain)'
evidence:
  quality_rating: C
  n_studies: 0
  primary_citation: Jamie Hartmann-Boyce et al. 2025. "Oral nicotine pouches for cessation or reduction
    of use of other tobacco or nicotine products.." https://doi.org/10.1002/14651858.CD016220.pub2
  supporting_citations:
  - No population-level studies identified in systematic review
  - Sought interrupted/multiple time-series studies but found none
  - Evidence gap explicitly noted by review authors
  doi: 10.1002/14651858.CD016220.pub2
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: No evidence exists on the population-level effects of ONP availability on smoking prevalence
  - this represents a critical evidence gap for tobacco control policy
spatial_variation:
  varies_by_geography: true
  variation_notes: ONP emerged in late 2000s but gained global market presence since 2016; regulatory
    environments vary by jurisdiction affecting availability and marketing
structural_competency:
  equity_implications: The absence of population-level evidence is itself structurally significant. Regulatory
    decisions about novel nicotine products are being made without understanding of population health
    impacts. This gap may differentially affect communities with different regulatory environments, marketing
    exposures, and access to cessation resources. Industry claims of harm reduction potential remain unsubstantiated
    at the population level.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.888981'
  extraction_confidence: low
  prompt_version: 2.1-canonical-validated
